TABLE 2.
Univariable and multivariable binary logistic regression models for undergoing definitive treatment among 1750 cT4b tumors.
| Univariable | Multivariable | ||||
|---|---|---|---|---|---|
| N | OR (95% CI) | p‐value | aOR a (95% CI) | p‐value | |
| Age at diagnosis (years) | 1385 | 0.97 (0.97–0.98) | <.001 | 0.97 (0.96–0.98) | <.001 |
| Sex | |||||
| Male | Ref | ||||
| Female | 0.86 (0.7–1.04) | .126 | |||
| Race | |||||
| White | Ref | ||||
| Black | 0.85 (0.62–1.16) | .305 | |||
| Other | 1.03 (0.68–1.56) | .881 | |||
| CDCS | |||||
| 0 | Ref | ||||
| ≥1 | 0.83 (0.65–1.07) | .146 | |||
| Histology | |||||
| Adenocarcinoma | 272 | Ref | Ref | ||
| Adenoid cystic carcinoma | 286 | 1.06 (0.78–1.44) | .700 | 0.90 (0.63–1.28) | .547 |
| Neuroendocrine carcinoma | 218 | 0.81 (0.58–1.14) | .227 | 0.81 (0.55–1.20) | .293 |
| Mucoepidermoid carcinoma | 17 | 0.85 (0.38–1.88) | .681 | 1.67 (0.61–4.60) | .320 |
| Melanoma | 178 | 0.45 (0.31–0.66) | <.001 | 0.57 (0.37–0.90) | .016 |
| Esthesioneuroblastoma | 79 | 1.55 (1.02–2.38) | .042 | 1.53 (0.91–2.58) | .113 |
| Undifferentiated carcinoma | 335 | 0.93 (0.69–1.26) | .643 | 0.91 (0.64–1.28) | .580 |
| Primary site | |||||
| Nasal cavity | Ref | ||||
| Accessory sinus | 0.96 (0.78–1.17) | .667 | |||
| Nasopharynx | 0.79 (0.49–1.27) | .327 | |||
| Tumor diameter (cm) | 0.99 (0.97–1.02) | .511 | |||
| Clinical nodal metastasis | |||||
| No | 1086 | Ref | Ref | ||
| Yes | 299 | 0.56 (0.42–0.75) | <.001 | 0.49 (0.36–0.66) | <.001 |
| Distant metastasis | |||||
| No | Ref | ||||
| Yes | 0.00 (0.00–0.00) | .995 |
Abbreviations: aOR, adjusted odds ratio; CDCS, Charlson–Deyo comorbidity score; CI, confidence interval; CRT, chemoradiotherapy; cT, clinical tumor; OR, odds ratio; OS, overall survival; RT, radiotherapy. Bolded values indicate statistically significant results (p<0.05).
a
N = 1385; number of events: 491.